Brief: XOMA Earns $35 Mln Milestone Payment As Anti-TGFβ Antibody Enters Phase 3 Clinical Study In Metastatic Pancreatic Cancer

Xoma Royalty

04/11/2021 11:41

Nov 4 (Reuters) - XOMA Corp  XOMA.O :
    * XOMA EARNS $35 MILLION MILESTONE PAYMENT AS ANTI-TGFΒ
ANTIBODY ENTERS PHASE 3 CLINICAL STUDY IN METASTATIC PANCREATIC
CANCER

Source text for Eikon:  ID:nGNXccBgJ4 
Further company coverage:  XOMA.O 

 ((Reuters.Briefs@thomsonreuters.com;;))